Also found in: Dictionary, Wikipedia.


a broad-spectrumβ-lactam antibiotic effective against a wide variety of gram-positive and gram-negative organisms; used in treatment of intra-abdominal infections and bacterial meningitis.


Meronem (UK), Merrem I.V.

Pharmacologic class: Carbapenem

Therapeutic class: Anti-infective

Pregnancy risk category B


Inhibits bacterial cell-wall synthesis and penetrates gram-negative and gram-positive bacteria


Powder for injection: 500-mg and 1-g vials

Indications and dosages

Intra-abdominal infections

Adults: 1 g I.V. q 8 hours over 15 to 30 minutes by infusion or over 3 to 5 minutes as a bolus injection

Children weighing 50 kg (110 lb) or more: 1 g I.V. q 8 hours over 15 to 30 minutes by infusion or over 3 to 5 minutes as a bolus injection

Children ages 3 months and older weighing less than 50 kg (110 lb): 20 mg/kg q 8 hours over 15 to 30 minutes by infusion or over 3 to 5 minutes as a bolus injection

Bacterial meningitis

Children weighing 50 kg (110 lb) or more: 2 g I.V. q 8 hours over 15 to 30 minutes by infusion or over 3 to 5 minutes as a bolus injection

Children ages 3 month and older weighing less than 50 kg (110 lb): 40 mg/kg q 8 hours over 15 to 30 minutes by infusion or over 3 to 5 minutes as a bolus injection, to a maximum of 2 g q 8 hours

Complicated skin and skin-structure infections

Adults: 500 mg I.V. q 8 hours

Dosage adjustment

• Renal impairment

Off-label uses

• Acute pulmonary exacerbation caused by respiratory tract infection with susceptible organisms in cystic fibrosis patients


• Hypersensitivity to drug, its components, or other beta-lactams


Use cautiously in:
• sulfite sensitivity, renal disease, seizure disorder
• pregnant or breastfeeding patients
• children.


• For I.V. bolus, add 10 or 20 ml of sterile water to 500-mg or 1-g vial, respectively, to yield a concentration of 50 mg/ml. Shake until clear. Administer single dose over 3 to 5 minutes.
• For intermittent I.V. infusion, piggyback vials can be reconstituted with compatible I.V. solution (0.9% sodium chloride or 5% dextrose) to yield a concentration of 2.5 to 50 mg/ml. Or vials can be reconstituted as for direct I.V. injection and added to compatible I.V. solution for further dilution. To reconstitute and administer ADD-Vantage systems, follow manufacturer's instructions. Infuse drug over 15 to 30 minutes.
• Use diluted solution immediately, if possible.

Adverse reactions

CNS: headache, insomnia, dizziness, drowsiness, weakness, seizures

CV: hypotension, phlebitis, palpitations, heart failure, cardiac arrest, myocardial infarction

GI: nausea, vomiting, diarrhea, constipation, tongue discoloration, oral candidiasis, glossitis, pseudomembranous colitis

GU: vaginal candidiasis

Hematologic: anemia, eosinophilia, leukopenia, bone marrow depression, thrombocytopenia, neutropenia

Musculoskeletal: myoclonus

Respiratory: chest discomfort, dyspnea, hyperventilation

Skin: rash, urticaria, pruritus, erythema at injection site

Other: altered taste, fever, pain, fungal infection, anaphylaxis


Drug-drug.Probenecid: increased meropenem blood level

Drug-diagnostic tests.Alanine aminotransferase, alkaline phosphatase, amylase, aspartate aminotransferase, bilirubin, blood urea nitrogen, eosinophils, gamma-glutamyl transpeptidase, lactate dehydrogenase, lipase: increased values

Hematocrit, hemoglobin, platelets, neutrophils, white blood cells: decreased values

International Normalized Ratio, partial thromboplastin time, prothrombin time: increased or decreased values

Patient monitoring

• Collect specimens for culture and sensitivity testing as needed. However, be aware that drug therapy may start pending results.

Monitor patient for hypersensitivity reaction or anaphylaxis. If either occurs, stop infusion immediately and initiate emergency treatment.
• Monitor for CNS irritability and seizures.
• In prolonged therapy, evaluate hematopoietic, renal, and hepatic function and watch for overgrowth of nonsusceptible organisms.
• If diarrhea occurs, check for pseudomembranous colitis and obtain stool cultures.
• Obtain hearing tests in child being treated for bacterial meningitis.

Patient teaching

• Advise patient to report such adverse reactions as CNS irritability, diarrhea, rash, shortness of breath, or pain at infusion site.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.


/mer·o·pen·em/ (-pen´em) a broad-spectrum antibacterial effective against a wide variety of gram-positive and gram-negative organisms; used in the treatment of intra-abdominal infections and bacterial meningitis.


a miscellaneous antiinfective.
indications It is used to treat serious infections caused by Streptococcus pneumoniae, group A beta-hemolytic streptococci, enterococcus, Klebsiella, Proteus, Escherichia coli, Pseudomonas aeruginosa, Bacteroides fragilis, and B. thetaiotaomicron. It is also used to treat appendicitis and peritonitis caused by the viridans group of streptococci, as well as bacterial meningitis.
contraindications Known hypersensitivity to meropenem or imipenem prohibits its use.
adverse effects Life-threatening effects are seizures, pseudomembranous colitis, hepatitis, eosinophilia, neutropenia, and anaphylaxis. Other adverse effects include fever, somnolence, dizziness, weakness, myoclonia, diarrhea, nausea, vomiting, glossitis, hypotension, palpitations, decreased hemoglobin and hematocrit, urticaria, pain at the injection site, phlebitis, erythema at the injection site, chest discomfort, dyspnea, and hyperventilation. Common side effects are headache, rash, and pruritus.


A CARBAPENEM antibiotic drug. A brand name is Meronem.
References in periodicals archive ?
Irrespective of this, It automatically ends with the entry into force of the exclusive agreement for meropenem, Atc j01dh02, As a result of a formal award procedure in accordance with the regulations of part 4 of the gwb with one or more contractual partners.
Among the [beta]-lactam comparator agents tested, only meropenem was more active than ceftolozane-tazobactam against Klebsiella species irrespective of the resistant phenotype (Table 2).
Other antibiotics tested were: imipenem, meropenem, tazobactum, amikacin, cefoperazone sulbactam, gentamicin, cefepime, ceftazidime, co-amoxiclav, ticarcillin, aztreonam, cefoperazone, co-trimoxazole, cefotaxime, cefixime, ceftriaxone, pipemidic acid and ampicillin.
34% of the Pseudomonas aeruginosa isolates were sensitive to Imipenem and Meropenem.
In the presented cases, linezolid (due to high cerebrospinal fluid penetration) and meropenem (that was preferred to imipenem due to risk for epileptic episodes) ([6,7]) were used.
Antimicrobial discs of piperacillin/tazobactam (TZP; 100/10 ug/ml), amikacin (AK; 30 ug/ml), ciprofloxacin (CIP; 5 ug/ml), ceftazidime (CAZ; 30 ug/ml), meropenem (MEM; 10 ug/ml) and aztreonam (ATM; 30 ug/ml) were obtained from Oxoid.
The susceptibility of bacterial isolates was evaluated for the following antibiotics: ampicillin, amoxicillin plus clavulanic acid, piperacillintazobactam, cefuroxime, cefoxitin, ceftriaxone, ceftazidime, cefepime, ertapenem, meropenem, imipenem, ciprofloxacin, gentamicin, amikacin, co-trimoxazole, tigecycline and colistin.
The antibacterial sensitivity pattern of isolated NFGNB as a pathogen showed that 95% of P aeruginosa were sensitive to Imipenem & Meropenem, 90% were sensitive to Piperacillin tazobactum , 85% were sensitive to CeftazidimeSulbactam,65 % were sensitive to Amikacin, 20% for Piperacillin and 40% for Co-trimoxazole.
Antimicrobial therapy was changed empirically to meropenem (1,000 mg 3x/d) on day 2.
In our study, we determine the minimum inhibitory concentration (MIC) for sulbactam/tazobactam individually and in vitro synergistic activity of both in combination with meropenem and colistin against multidrug-resistant A.
Meropenem was taken as a representative of the Group 2 carbapenems (meropenem, imipenem, doripenem).